Eureka Therapeutics Inc. announced on 7/17/18 that Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against an undisclosed target to be used for the potential development and commercialization of therapies for cancer patients.
